News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) - The Final Phase 3a Trial for IDegLira Completed, and FIAsp Approved for Phase 3 Development



12/19/2012 9:12:34 AM

BAGSVAERD, DENMARK--(Marketwire - December 19, 2012) - Company Announcement No 83 2012: http://hugin.info/2013/R/1666389/540820.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1666389]


Novo Nordisk A/S
Novo Alle , DK-2880
Bagsvaerd, Danmark
*T. Tlf. +45 44 44 88 88
*F. Fax +45 44 44 49 05


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES